Skip to main content
. 2021 Jun 28;21(2):191–202. doi: 10.5230/jgc.2021.21.e18

Fig. 4. (A) Fluorescence intensity of affibody-IRDye800CW. At 30 minutes and 1 hours after injection of the probe, a slight signal was observed, which washed out immediately. (B) Ex vivo images of affibody-IRDye800CW. All fluorescence accumulated to the kidney after 72 hours, suggesting that affibody-IRDye800CW cannot detect HER2-positive tumors effectively. (C) Images of trastuzumab-IRDye800CW and affibody-IRDye800CW with an adjusted scale bar. When adjusting the scale bar, fluorescence was identified n HER2-positive tumors at 30 minutes after injection.

Fig. 4

HER2 = human epidermal receptor 2.